Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO

Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., former CMO of Arena Pharmaceuticals and CEO of CorHepta Pharmaceuticals, has been appointed as President and Head of Research & Development. Additionally, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, John Adams, Ph.D. has been appointed Chief Scientific Officer. Additionally, Vince Aurentz will join Inhibikase Board of Directors He served as Executive Vice President and Chief Business Officer at Arena Pharmaceuticals.